Assessment of the quality of medication information for patients in Spain.

Abstract:

OBJECTIVE:To analyze the extent to which Spanish leaflets and drug information on the Net met quality criteria. RESEARCH DESIGN AND METHODS:A descriptive study was conducted comparing readability (REA) and comprehensibility (COM) criteria of a random sample of 77 marketed products of the 12 active ingredients most frequently sold in 2010 in Spain. Leaflets were approved by the Spanish Agency for Medication (AEMPS). Flesch index, DISCERN, ELF, MIDAS and CIRF scales were used to evaluate quality criteria. RESULTS:COM assessment yielded between 63 and 77% of the maximum possible scores on the scales. None of the websites or leaflets met all the quality criteria of the DISCERN, CIRF or MIDAS scales. Four (3%) leaflets met all the 22 quality criteria of ELF. The leaflets showed shortcomings regarding: medication benefits (17 required substantial improvements, 31.5%), correct forms of storage (13, 24.1%), contraindications (12, 22.2%), side effects (11, 20.4%) and precautions to be taken (9, 16.7%). CONCLUSIONS:The quality of the information approved by the AEMPS is superior to that which can be found by surfing the Net. More specific information on precautions, complications and how to avoid common patient errors would allow patients the best chance to contribute to their own clinical safety.

journal_name

Expert Opin Drug Saf

authors

Mira JJ,Lorenzo S,Pérez-Jover V,Navarro I,Martín de Rosales AM,Lara C

doi

10.1517/14740338.2013.744965

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

9-18

issue

1

eissn

1474-0338

issn

1744-764X

journal_volume

12

pub_type

杂志文章
  • The adverse-effect profile of lacosamide.

    abstract::Introduction: Lacosamide has been used in epilepsy patients in the United States, Europe and Asia since it was approved by the FDA in 2008. Many patients have benefited from this drug as a new generation of sodium channel blocker. With the worldwide use of this drug, its adverse effects have gradually emerged, especia...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2020.1713089

    authors: Li J,Sun M,Wang X

    更新日期:2020-02-01 00:00:00

  • Cardiovascular effects of anti-diabetes drugs.

    abstract:INTRODUCTION:Cardiovascular disease remains the major contributor to morbidity and mortality in diabetes. From the need to reduce cardiovascular risk in diabetes and to ensure that such risk is not exacerbated by drug treatments, governmental regulators and drug manufacturers have focused on clinical trials evaluating ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2016.1195368

    authors: Younk LM,Lamos EM,Davis SN

    更新日期:2016-09-01 00:00:00

  • A safety evaluation of evolocumab.

    abstract:INTRODUCTION:Evolocumab is an injectable, fully human monoclonal antibody and a member of the newest class of low density lipoprotein cholesterol (LDL-C) lowering agents called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The PCSK9 inhibitors are the most significant advance in lipid therapy since ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2018.1389892

    authors: Roth EM

    更新日期:2018-01-01 00:00:00

  • The risks associated with prenatal antidepressant exposure: time for a precision medicine approach.

    abstract:INTRODUCTION:The prevalence of depression in pregnancy is over 10% and a significant proportion of pregnant women use antidepressant medication. The safety of antidepressants in pregnancy is controversial, partly due to methodological challenges. The conflicting results in the literature may, however, also be due to di...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1341872

    authors: Pedersen LH

    更新日期:2017-08-01 00:00:00

  • Prospects for MEK inhibitors for treating cancer.

    abstract:INTRODUCTION:The MAPK pathway is a signaling network that plays a key role in many normal cellular processes and in a large number of human malignancies. One of its effectors, MEK, is essential for the carcinogenesis of different tumors. In recent years, several drugs able to inhibit MEK have been assessed in clinical ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2014.892578

    authors: Martin-Liberal J,Lagares-Tena L,Larkin J

    更新日期:2014-04-01 00:00:00

  • The safety of monoclonal antibodies for treatment of colorectal cancer.

    abstract:INTRODUCTION:Monoclonal antibodies such as bevacizumab, ramucirumab, cetuximab and panitumumab play an important role in the treatment of metastatic colorectal cancer (mCRC). With the introduction of these drugs considerable improvements in both progression-free survival (PFS) and overall survival (OS) were achieved. H...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2016.1167186

    authors: Berger MD,Lenz HJ

    更新日期:2016-06-01 00:00:00

  • From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.

    abstract:INTRODUCTION:Pharmacologic vitreolysis is a strategy used to treat anomalous posterior vitreous detachment, by weakening vitreoretinal adhesion with an intravitreal drug. Pharmacologic vitreolysis facilitates surgery, and abnormalities of the vitreoretinal interface including vitreomacular traction (VMT) and early stag...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2016.1208169

    authors: Morescalchi F,Gambicorti E,Duse S,Costagliola C,Semeraro F

    更新日期:2016-09-01 00:00:00

  • The safety and efficacy of antithyroid drugs.

    abstract::Thionamides, selective inhibitors of thyroid peroxidase-mediated iodination by tyrosine residues in thyroglobulin, have been effectively used in the treatment of hyperthyroidism. The choices for initial treatment of patients with Graves' disease differ in various countries, and many physicians around the world prefer ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.5.1.107

    authors: Azizi F

    更新日期:2006-01-01 00:00:00

  • Drug-induced aseptic meningitis.

    abstract::Drug-induced aseptic meningitis (DIAM) is an important entity. This article reviews the literature on this rare idiosyncratic event which may occur after local or systemic drug administration. The data on this adverse reaction is predominantly collated from anecdotal case reports and case series. ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.4.2.285

    authors: Hopkins S,Jolles S

    更新日期:2005-03-01 00:00:00

  • Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.

    abstract::Background: This study aimed to measure the association of various H1-antihistamines (H1A) with Torsade de Pointes (TdP), and present a comprehensive overview of H1A-induced TdP cases reported to the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: All H1A-induced TdP cases (n = 406) were ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2021.1846717

    authors: Ali Z,Ismail M,Khan F,Sajid H

    更新日期:2021-01-01 00:00:00

  • Osteonecrosis of the jaw: what do bisphosphonates do?

    abstract::Osteonecrosis of the jaw is a new disease, partly caused by bisphosphonates. It is commonly assumed that the bisphosphonates somehow cause cell death (osteocyte necrosis) within the jawbone, which makes it prone to chronic infection. In this article, an alternative pathogenetic theory is suggested, based on the normal...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740338.5.6.743

    authors: Aspenberg P

    更新日期:2006-11-01 00:00:00

  • Current strategies for managing intestinal failure-associated liver disease.

    abstract::Introduction: Intestinal failure-associated liver disease (IFALD) refers to hepatic dysfunction that results from prolonged parenteral nutrition (PN) use. IFALD is multifactorial in origin and remains a major cause of morbidity and mortality. Prior to 2004, IFALD was associated with mortality as high as 90% in infants...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2021.1867099

    authors: Secor JD,Yu L,Tsikis S,Fligor S,Puder M,Gura KM

    更新日期:2020-12-30 00:00:00

  • The safety of prescribing opioids in pediatrics.

    abstract:INTRODUCTION:Pain management has become a widely discussed topic throughout all medical subspecialties. Although pediatric pain management has evolved significantly in its recent history, there is continued interest in the adequacy of pain treatment, both in the acute inpatient setting as well as the postoperative and ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.834045

    authors: Martin DP,Bhalla T,Beltran R,Veneziano G,Tobias JD

    更新日期:2014-01-01 00:00:00

  • Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.

    abstract:INTRODUCTION:Sulfasalazine (SASP) is a drug commonly used in the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease (CD) and rheumatoid arthritis (RA). A high incidence of side effects limits therapy with this drug. Getting a wider knowledge of drug pharmacology, indications a...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2011.529898

    authors: Linares V,Alonso V,Domingo JL

    更新日期:2011-03-01 00:00:00

  • The safety of albiglutide for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. It has significantly less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as competitor agents such as liraglutide...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1351538

    authors: Rendell MS

    更新日期:2017-09-01 00:00:00

  • Statin use and the risk of kidney cancer: a population-based case-control study.

    abstract:OBJECTIVE:To investigate whether the use of statins was associated with kidney cancer risk. METHODS:We conducted a population-based case-control study in Taiwan. Cases consisted of all patients who were aged 50 years and older, and had a first-time diagnosis of kidney cancer for the period between 2005 and 2009. The c...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2012.678831

    authors: Chiu HF,Kuo CC,Kuo HW,Lee IM,Lee CT,Yang CY

    更新日期:2012-07-01 00:00:00

  • Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients.

    abstract:INTRODUCTION:Approximately 40-50% of patients with cutaneous melanoma harbor point mutations in BRAF. BRAF and MEK inhibitors in combination are now a standard therapy for advanced BRAFV600-mutated melanoma. Nevertheless, survival rates with the combination are limited, highlighting the need for further therapeutic imp...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1817376

    authors: Indini A,Mandalà M

    更新日期:2020-10-01 00:00:00

  • Statin use and the risk of breast cancer: a population-based case-control study.

    abstract:OBJECTIVE:The aim of this study was to investigate whether the use of statins was associated with breast cancer risk. BACKGROUND:Experimental studies have shown that statins have potential protective effects against cancer. METHODS:We conducted a population-based case-control study in Taiwan. Cases consisted of all p...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2014.885949

    authors: Chan TF,Wu CH,Lin CL,Yang CY

    更新日期:2014-03-01 00:00:00

  • Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.

    abstract:INTRODUCTION:In settings where HIV is prevalent in heterosexual populations, pregnancy and postpartum breastfeeding periods can be associated with substantial HIV acquisition risk. Pre-exposure prophylaxis (PrEP) with daily oral tenofovir disoproxil fumarate (TDF)/emtricitabine is an attractive HIV prevention option fo...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1338271

    authors: Mugwanya KK,John-Stewart G,Baeten J

    更新日期:2017-07-01 00:00:00

  • Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease.

    abstract:INTRODUCTION:Despite the significant advances in the pharmacological and interventional management of patients with cardiovascular disease (CVD) over the last decades, cardiovascular mortality remains the leading cause of death. Large randomized clinical trials have investigated the efficacy and safety of different ant...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2018.1524869

    authors: Romano S,Buccheri S,Mehran R,Angiolillo DJ,Capodanno D

    更新日期:2018-10-01 00:00:00

  • Fracture risk associated with chronic use of bisphosphonates: evidence today.

    abstract:IMPORTANCE OF THE FIELD:Bisphosphonates are the most widely used antiresorptive agents for the treatment of osteoporosis. However, the cumulative bisphoshonate exposure and its association with atypical fragility fractures, and the optimum duration of treatment remain obscure. AREAS COVERED IN THIS REVIEW:This review ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2010.517192

    authors: Charopoulos I,Orme S,Giannoudis PV

    更新日期:2011-01-01 00:00:00

  • Prescribing in 2019: what are the safety concerns?

    abstract:INTRODUCTION:Unintended harm from prescribing errors remains a prevalent concern in healthcare leading to significant morbidity and mortality around the world. Prescribers face new challenges to their practice in modern times such as increasingly complex health-care systems, an aging population with increasing multimor...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1571038

    authors: Coleman JJ

    更新日期:2019-02-01 00:00:00

  • Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients.

    abstract:INTRODUCTION:ACE-inhibitors (ACEI) and diuretics are the typical first-line antihypertensive drugs with complementary mechanisms of action. The present paper is summarizing the evidence supporting the efficacy of their combination in a broad range of hypertensive patients. AREAS COVERED:This source of data is differen...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1836151

    authors: Borghi C,Soldati M,Bragagni A,Cicero AFG

    更新日期:2020-12-01 00:00:00

  • High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.

    abstract:INTRODUCTION:In 1998, high-dose interleukin-2 (IL-2) was the first immunotherapy approved for the treatment of metastatic melanoma based on durable objective responses documented in a subset of patients but widespread utilization was limited by significant toxicity. Advances in targeted therapy and the emergence of T c...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1382472

    authors: Marabondo S,Kaufman HL

    更新日期:2017-12-01 00:00:00

  • Tigecycline : a critical safety review.

    abstract:INTRODUCTION:The emergence of multidrug-resistant (MDR) infections has been extensively observed worldwide and has become a priority issue over past decade. Tigecycline , a broad spectrum antibiotic covering against many MDR organisms, has been widely used. However, recent meta-analysis studies have raised a concern fo...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2015.997206

    authors: Kaewpoowat Q,Ostrosky-Zeichner L

    更新日期:2015-02-01 00:00:00

  • Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance.

    abstract::Objectives: Sensory adverse drug reactions (ADRs) are generally expected to be transient in nature. However, spontaneous reports describe frequently these events as long-lasting or unresolved. In this study, the authors reviewed the Eudravigilance publicly accessible database to describe the volume and expectedness of...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2019.1676724

    authors: Ferraro S,Convertino I,Leonardi L,Blandizzi C,Tuccori M

    更新日期:2019-12-01 00:00:00

  • Adrenaline in anaphylaxis treatment. Balancing benefits and harms.

    abstract:INTRODUCTION:Although anaphylaxis is a relatively common disorder, clinicians and scientists have debated on how to best define and manage this condition. The current recommendations are focused on the central role of adrenaline, but evidence in support of this therapeutic approach is modest, mainly for the lack of wel...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2016.1167870

    authors: Cervellin G,Sanchis-Gomar F,Lippi G

    更新日期:2016-06-01 00:00:00

  • The risk of cardiovascular complications with current obesity drugs.

    abstract:INTRODUCTION:Obesity is associated with an increased risk of cardiovascular morbidity and mortality. Four medications are approved by the US Food and Drug Administration (FDA) for chronic weight management when used as an adjunct to a reduced-calorie diet and increased physical activity in adults. These medications res...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1806234

    authors: Chao AM,Wadden TA,Berkowitz RI,Quigley K,Silvestry F

    更新日期:2020-09-01 00:00:00

  • Efficacy and safety of mipomersen sodium (Kynamro).

    abstract:INTRODUCTION:Mipomersen is a first-in-class drug indicated as an adjunct to lipid-lowering medications and diet to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC) and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholes...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.793670

    authors: Hovingh K,Besseling J,Kastelein J

    更新日期:2013-07-01 00:00:00

  • Neuropsychiatric side effects of efavirenz therapy.

    abstract::The non-nucleoside analogue inhibitor of the reverse transcriptase, efavirenz (EFV), has become commonly used in highly active antiretroviral combination therapy in the treatment of HIV infection. Although being effective in suppressing plasma viral load, neuropsychiatric side effects have been reported in individuals...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.6.2.147

    authors: Arendt G,de Nocker D,von Giesen HJ,Nolting T

    更新日期:2007-03-01 00:00:00